

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

Restricted Use Drug -A Prescription Medication or Drug that may require Prior Approval and/or be subject to a limited dispensing amount.

Key Definitions		
CE	Coverage Exception	For Qualified Health Plans (QHP), this is a Non-Formulary drug excluded from coverage. If seeking coverage, a Coverage Exception Form must be submitted for review. The coverage exception form can be found on the link below: https://www.myprime.com/content/dam/prime/memberportal/forms/2018/FullyQualified/Other/ALL/BCBSND/COMMERCIAL/NDIVLDRUG/ND_HIM_Coverage_Exception.pdf OR https://www.myprime.com/en/coverage-exception-form.html
F	Formulary Drug	A Brand Name or Generic Prescription Drug that has been determined to be safe, therapeutically effective, high quality, and cost-effective as determined by a committee of Physicians and Pharmacists based on current data.
MED	Medical Drug	A medical benefit drug that requires Prior Approval (Precertification) to be completed by the Medical Pharmacy Solutions Team at Prime Therapeutics. Precertification information for medical drugs can be found on the link below: www.gatewaypa.com/policydisplay/52
MED+	Medical Drug Available on Pharmacy Benefit	A drug that requires Prior Approval (Precertification) through the medical benefit prior authorization process but is payable under the pharmacy benefit. Precertification information for medical drugs can be found on the link below: www.bcbsnd.com/providers/policies-precertification/prior-authorization
MED ND	Medical Drug review BCBSND	A medical benefit drug that requires Prior Approval (Precertification) through BCBSND. Precertification information for medical drugs can be found on the link below: www.bcbsnd.com/providers/policies-precertification/prior-authorization
NF	Non-Formulary Drug	A Prescription Medication or Drug that is not a Formulary Drug
PA	Prior Approval	A drug that requires Prior Approval. Prior authorization form for pharmacy drugs can be found on the link below: https://www.myprime.com/en/forms/coverage-determination/prior-authorization.html
QHP	Qualified Health Plan	Health Insurance Market Individual, Small Group Formulary and BlueValue Formulary

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
ABECMA	IDCABTAGENE VICLEUCEL	MED	Q2055
ABRAXANE	PACLITAXEL PROTEIN-BOUND	MED	J9264
ABRILADA	ADALIMUMAB-AFZB	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
ACTEMRA IV vial (Healthcare Administered)	TOCILIZUMAB	MED	J3262
ACTEMRA prefilled syringe (Self-Administered)	TOCILIZUMAB	PA	
ADAKVEO	CRIZANLIZUMAB-TMCA	MED	J0791
ADALIMUMAB-AATY	ADALIMUMAB-AATY	CE, PA	
ADALIMUMAB-ADAZ	ADALIMUMAB-ADAZ	CE, PA	
ADALIMUMAB-ADBIM	ADALIMUMAB-ADBIM	CE, PA	
ADALIMUMAB-FKJP	ADALIMUMAB-FKJP	CE, PA	
ADALIMUMAB-RYVK	ADALIMUMAB-RYVK	CE, PA	
ADAPALENE/BENZOYL PEROXIDE	ADAPALENE-BENZOYL PEROXIDE	CE, PA	
ADBRY	TRALOKINUMAB-LDRM	PA	
ADCETRIS	BRENTUXIMAB	MED	J9042
ADCIRCA	TADALAFIL	PA, CE (Brand only)	
ADEMPAS	RIOCIGUAT	PA	
ADLYXIN	LIXISENATIDE	CE, PA	
ADMELOG	INSULIN LISPRO	CE, PA	
ADMELOG SOLOSTAR	INSULIN LISPRO	CE, PA	
ADSTILADRIN	NADOFARAGENE FIRADENOV-VNCG	MED	J9029
ADVAIR DISKUS (Brand only)	FLUTICASONE/SALMETEROL	CE (Brand only)	
ADVATE	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM)	PA	
ADYNOVATE	ANTIHEMOPHILIC FACTOR RECOMB PEGYLATED	PA	
ADZYNMA	ADAMTS13 RECOMBINANT-KRHN	MED	J7171
AFINITOR/AFINITOR DISPERZ	EVEROLIMUS	PA	
AFREZZA	INSULIN REGULAR (HUMAN) INHALATION POWDER	CE, PA	
AFSTYLA	ANTIHEMOPHILIC FACT RCMB SINGLE CHAIN	PA	
AGAMREE	VAMOROLONE	CE, PA	
AHZANTIVE	AFLIBERCEPT-MRBB	MED	J3590; C9399
AIMOVIG	ERENUMAB	PA	
AJOVY	FREMANEZUMAB	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
AKEEGA	NIRAPARIB TOSYLATE-ABIRATERONE ACETATE	CE, PA	
AKLIEF	TRIFAROTENE	CE, PA	
AKYNZEO IV	FOSNETUPITANT/PALONOSETRON	MED	J1454
ALDURAZYME	LARONIDASE SOLN	MED	J1931
ALECENSA	ALECTINIB	PA	
ALOGLIPTIN	ALOGLIPTIN BENZOATE	CE, PA	
ALOGLIPTIN/METFORMIN HCL	ALOGLIPTIN-METFORMIN	CE, PA	
ALOGLIPTIN/PIOGLITAZONE	ALOGLIPTIN-PIOGLITAZONE	CE, PA	
ALPHANATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN)	PA	
ALPHANINE SD	COAGULATION FACTOR IX	PA	
ALPROLIX	COAGULATION FACTOR IX	PA	
ALTRENO	TRETINOIN	CE, PA	
ALTUVIIO	ANTIHEMOPHILIC FACT RCMB	PA	
ALUNBRIG	BRIGATINIB	PA	
ALVAIZ	ELTROMBOPAG CHOLINE	CE, PA	
ALVESCO	CICLESONIDE	CE	
ALYFTREK	VANZACAFTOR-TEZACAFTOR-DEUTIVACAFTOR	CE, PA	
ALYGLO	IMMUNE GLOBULIN (IV)	MED	J1552
ALYMSYS	BEVACIZUMAB	MED	Q5126
ALYQ	TADALAFIL	PA	
AMJEVITA	ADALIMUMAB-ATTO	CE, PA	
AMONDYS-45	CASIMERSEN	MED	J1426
AMPYRA	DALFAMPRIDINE	PA, CE (Brand only)	
AMTAGVI	LIFILEUCEL	MED	J9999; C9399
AMVUTTRA	VUTRISIRAN	MED	J0225
ANKTIVA	NOGAPENDEKIN ALFA INBAK-PMLN	MED	J9028
APHEXDA	MOTIXAFORTIDE ACETATE	MED	J2277
APIDRA	INSULIN GLULISINE	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
APIDRA SOLOSTAR	INSULIN GLULISINE	CE, PA	
ARAZLO	TAZAROTENE	PA, CE (Brand only)	
ARCALYST	RILONACEPT	PA	
ASCENIV	IMMUNE GLOBULIN (HUMAN)-SLRA IV	MED	J1554
ATRALIN	TRETINOIN	CE, PA	
ATTRUBY	ACORAMIDIS HCL	CE, PA	
AUBAGIO	TERIFLUNOMIDE	PA, CE (Brand only)	
AUCATZYL	OBECABTAGENE AUTOLEUCCEL	MED	J9999; C9399
AUGTYRO	REPOTRECTINIB	CE, PA	
AUSTEDO	DEUTETRABENAZINE	PA	
AUSTEDO XR	DEUTETRABENAZINE	PA	
AVASTIN (cancer indications only require PA)	BEVACIZUMAB	MED	J9035
AVITA	TRETINOIN	PA	
AVONEX	INTERFERON β -1a	PA	
AVSOLA	INFLIXIMAB-AXXQ	MED	Q5121
AVZIVI	BEVACIZUMAB-TNJV	MED	J9999; C9399
AXTLE	PEMETREXED DIPOTASSIUM	MED	J9292
AYVAKIT	AVAPRITINIB	PA	
AZEDRA	IOBENGUANE	MED	A9590
BACLOFEN	BACLOFEN SUSP 25 MG/5ML, ORAL SOLN 5 MG/5ML	CE, PA	
BAFIERTAM	MONOMETHYL FUMARATE	CE, PA	
BALVERSA	ERDAFITINIB	PA	
BAVENCIO	AVELUMAB	MED	J9023
BELRAPZO	BENDAMUSTINE	MED	J9036
BENDAMUSTINE	BENDAMUSTINE	MED	J9036
BENDEKA	BENDAMUSTINE	MED	J9034
BENEFIX	COAGULATION FACTOR IX	PA	
BENLYSTA (IV) vial (Healthcare Administered)	BELIMUMAB	MED	J0490

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
BENLYSTA auto-injector or prefilled syringe (Self-Administered)	BELIMUMAB	PA	
BEOVU	BROLUCIZUMAB-DBLL	MED	J0179
BEQVEZ	FIDANACOGENE ELAPARVOVEC-DZKT	MED	J1414
BERINERT	C1 ESTERASE INHIBITOR (HUMAN)	MED	J0597
BESREMI	ROPEGINTERFERON ALFA-2B-NJFT	PA	
BETASERON	INTERFERON β -1b	PA	
BIMZELX	BIMEKIZUMAB-BKZX	CE, PA	
BIVIGAM	IMMUNE GLOBULIN (HUMAN) IV	MED	J1556
BIZENGRI	ZENOCUTUZUMAB-ZBCO	MED	J9999; C9399
BKEMV	ECULIZUMAB-AEEB	MED	Q5139
BLINCYTO	BLINATUMOMAB	MED	J9039
BOSULIF	BOSUTINIB	CE, PA	
BRAFTOVI	ENCORAFENIB	PA	
BRENZAVVY	BEXAGLIFLOZIN TAB	CE, PA	
BREXAFEMME	IBREXAFUNGERP CITRATE	CE, PA	
BREYANZI	LISOCABTAGENE MARALEUCCEL	MED	Q2054
BRIUMVI	UBLITUXIMAB-XIY	MED	J2329
BRUKINSA	ZANUBRUTINIB	PA	
BYDUREON BCISE	EXENATIDE	CE, PA	
BYDUREON PEN	EXENATIDE	CE, PA	
BYETTA	EXENATIDE	CE, PA	
BYOOVIZ	RANIBIZUMAB-NUNA	MED	Q5124
CABAZITAXEL	CABAZITAXEL	MED	J9064
CABOMETYX	CABOZANTINIB	PA	
CABTREO	ADAPALENE-BENZOYL PEROXIDE-CLINDAMYCIN	CE, PA	
CALQUENCE	ACALABRUTINIB	PA	
CAMZYOS	MAVACAMTEN	PA	
CAPRELSA	VANDETANIB	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
CARBAGLU	CARGLUMIC ACID	PA, CE (Brand only)	
CARVYKTI	CILTACABTAGENE AUTOLEUCEL	MED	Q2056
CASGEVY	EXAGAMGLOGENE AUTOTEMCEL	MED	J3392
CERDELGA	ELIPLUSTAT TARTRATE	PA	
CEREZYME	IMIGLUCERASE	MED	J1786
CIBINQO	ABROCITINIB	PA, CE	
CIMERLI	RANIBIZUMAB-EQRN	MED	Q5128
CIMZIA lyophilized powder vial (Healthcare Administered)	CERTOLIZUMAB	MED	J0717
CIMZIA prefilled syringe (Self-Administered)	CERTOLIZUMAB	PA	
CINQAIR	RESLIZUMAB	MED	J2786
CINRYZE	C1 ESTERASE INHIBITOR (HUMAN)	MED	J0598
COAGADEX	COAGULATION FACTOR X	PA	
COLUMVI	GLOFITAMAB-GXBM	MED	J9286
COMETRIQ	CABOZANTINIB S-MAL	PA	
COPAXONE	GLATIRAMER	PA, CE (Brand only)	
COPIKTRA	DUVELSIB	PA	
CORLANOR	IVABRADINE HCL	PA	
CORTROPHIN	CORTICOTROPIN INJ GEL 80 UN	CE, PA	
COSELA	TRILACICLIB	MED	J1448
COSENTYX IV (Healthcare Administered)	SECUKINUMAB	MED	J3247
COSENTYX, COSENTYX UNOREADY	SECUKINUMAB	PA	
COTELLIC	COBIMETINIB	PA	
CRESEMBA cap	ISAVUCONAZONIUM	PA	
CRESEMBA injection	ISAVUCONAZONIUM SULF FOR IV SOL	CE, PA	
CRYSVITA	BUROSUMAB -TWZA	MED	J0584
CUTAQUIG	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS	MED	J1551
CUVITRU	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS	MED	J1555
CYLTEZO	ADALIMUMAB-ADBIM	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
CYRAMZA	RAMUCIRUMAB	MED	J9308
DANYELZA	NAXITAMAB-GQGK	MED	J9348
DANZITEN	NILOTINIB TARTRATE	CE, PA	
DARZALEX	DARATUMUMAB	MED	J9145
DARZALEX FASPRO	TARATUMUMAB AND HYALURONIDASE-FIHJ	MED	J9144
DASATINIB	DASATINIB	CE, PA	
DAURISMO	GLASDEGIB	PA	
DEFLAZACORT	DEFLAZACORT	CE, PA	
DEXCOM G5 CGM RECEIVER, TRANSMITTER, SENSOR		PA	
DEXCOM G6 CGM RECEIVER, TRANSMITTER, SENSOR		PA	
DEXCOM G7 RECEIVER, TRANSMITTER, SENSOR		PA	
DIFFERIN	ADAPALENE	CE, PA	
DIHYDROERGOTAMINE NASAL SPRAY	DIHYDROERGOTAMINE MESYLATE NASAL SPRAY	CE, PA	
DOPTELET	AVATROMBOPAG MALEATE	CE, PA	
DUPIXENT	DUPILUMAB	PA	
DUROLANE	SODIUM HYALURONATE	MED	J7318
EBGLYSS	LEBRIKIZUMAB-LBKZ	CE, PA	
ELAHERE	MIREVETUXIMAB SORAVTANSINE-GYNX	MED	J9063
ELAPRASE	IDURSULFASE	MED	J1743
ELELYSO	TALIPLUCERASE ALFA	MED	J3060
ELEVIDYS	DELANDISTROGENE MOXEPARVOVEC-ROKL	MED	J1413
ELFABRIO	PEGUNIGALSIDASE ALFA-IWXJ	MED	J2508
ELOCTATE	ANTIHEMOPHILIC FACTOR RCMB (BDD-RFVIIIIC)	PA	
ELREXFIO	ELRANATAMAB-BCMM	MED	J1323
ELYXYB ORAL SOLUTION	CELECOXIB ORAL SOLUTION	CE, PA	
ELZONRIS	TAGRAXOFUSP	MED	J9269
EMFLAZA	DEFLAZACORT	CE, PA	
EMGALITY	GALCANEZUMAB	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
EMPAVELI	PEGCETACOPLAN	PA	
ENBREL	ETANERCEPT	PA	
ENDARI	GLUTAMINE	PA	
ENHERTU	FAM-TRASTUZUMAB DERUXTECAN-NXKI	MED	J9358
ENJAYMO	SUTIMLIMAB-JOME	MED	J1302
ENSPRYNG	SATRALIZUMAB-MWGE	PA	
ENTYVIO IV (Healthcare Administered)	VEDOLIZUMAB	MED	J3380
ENTYVIO pen-injector (Self-administered)	VEDOLIZUMAB	CE, PA	
ENZEEVU	AFLIBERCEPT-ABZV	MED	J3590; C9399
EPCLUSA	SOFOSBUVIR-VELPATASVIR 200-50 MG	PA	
EPCLUSA	SOFOSBUVIR-VELPATASVIR 400-100 MG	CE, PA	
EPCLUSA PELLETT PACK	SOFOSBUVIR-VELPATASVIR	PA	
EPIDIOLEX	CANNABIDIOL SOLN	PA	
EPIDUO	ADAPALENE-BENZOYL PEROXIDE	CE, PA	
EPIDUO FORTE	ADAPALENE-BENZOYL PEROXIDE	CE, PA	
EPKINLY	EPCORITAMAB-BYSP	MED	J9321
EPYSQLI	ECULIZUMAB-AAGH	MED	J3590; C9399
ERBITUX	CETUXIMAB	MED	J9055
ERIVEDGE	VISMODEGIB	PA	
ERLEADA	APALUTAMIDE	PA	
ERWINAZE	ASPARAGINASE	MED	J9019
ESBRIET	PIRFENIDONE	PA	
ESPEROCT	ANTIHEMOPHILIC FACTOR RECOMB GLYCOPEG-EXEI	PA	
EUFLEXXA	SODIUM HYALURONATE	MED	J7323
EVENITY	ROMOSOZUMAB	MED	J3111
EVKEEZA	EVINACUMAB-DGNB	MED	J1305
EVRYSDI	RISDIPLAM	PA	
EXKIVITY	MOBOCERTINIB SUCCINATE	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
EXONDYS-51	ETEPLIRSEN	MED	J1428
EXTAVIA	INTERFERON β -1b	PA	
EYLEA	AFLIBERCEPT	MED	J0178
EYLEA HD	AFLIBERCEPT	MED	J0177
FABHALTA	IPTACOPAN	PA	
FABIOR	TAZAROTENE	PA, CE (Brand only)	
FABRAZYME	AGALSIDASE BETA	MED	J0180
FARYDAK	PANOBINOSTAT LACTATE	CE, PA	
FASENRA	BENRALIZUMAB	MED	J0517
FASENRA prefilled autoinjector pen (Self-Administered)	BENRALIZUMAB	PA	
FERAHEME	FURUMOXYTOL	MED	Q0138
FIBRYGA	FIBRINOGEN CONC	PA	
FILSPARI	SPARSENTAN	PA	
FIRAZYR	ICATIBANT ACETATE	PA	
FIRDAPSE	AMIFAMPRIDINE	PA	
FLEBOGAMMA DIF	IMMUNE GLOBULIN (HUMAN) IV	MED	J1572
FLEQSUVY	BACLOFEN	CE, PA	
FLOVENT DISKUS	FLUTICASONE	CE	
FLOVENT HFA	FLUTICASONE	CE	
FOLOTYN	PRALATREXATE	MED	J9307
FORTEO	TERIPARATIDE	PA	
FOTIVDA	TIVOZANIB HCL	PA	
FREESTYLE LIBRE READER, SENSOR		PA	
FRUZAQLA	FRUQUINTINIB CAP	CE, PA	
FUROSCIX	FUROSEMIDE SUBCUTANEOUS	PA	
FUSILEV	LEVOLEUCOVORIN CALCIUM	MED	J0641
FYARRO	SIROLIMUS-ALBUMIN-BOUND	MED	J9331
FYLNETRA	PEGFILGRASTIM-PBBK	MED	Q5130

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
GALAFOLD	MIGALASTAT	PA	
GAMIFANT	EMAPALUMAB-LZSG	MED	J9210
GAMMAGARD LIQUID	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS	MED	J1569
GAMMAGARD S/D	IMMUNE GLOBULIN (HUMAN) IV	MED	J1566
GAMMAKED	IMMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS	MED	J1561
GAMMAPLEX	IMMUNE GLOBULIN (HUMAN) IV	MED	J1557
GAMUNEX-C	MMUNE GLOBULIN (HUMAN) IV OR SUBCUTANEOUS	MED	J1561
GAVRETO	PRALSETINIB	PA	
GAZYVA	OBINUTUZUMAB	MED	J9301
GEL-ONE	CROSS-LINKED HYALURONATE	MED	J7326
GELSYN-3	SODIUM HYALURONATE	MED	J7328
GENOTROPIN	SOMATROPIN	PA	
GENVISC 850	SODIUM HYALURONATE	MED	J7320
GILENYA	FINGOLIMOD	PA	
GILOTRIF	AFATINIB DIMALEATE	PA	
GIVLAARI	GIVOSIRAN SODIUM	MED	J0223
GLATOPA	GLATIRAMER	PA, CE (Brand only)	
GLEEVEC	IMATINIB MESYLATE	PA, CE (Brand only)	
GRASTEK	TIMOTHY GRASS POLLEN ALLERGEN EXTRACT	PA	
H P ACTHAR GEL	CORTICOTROPIN INJ GEL	PA	
HADLIMA	ADALIMUMAB-BWWD SOLN	PA	
HAEGARDA	C1 ESTERASE INHIBITOR	PA	
HALAVEN	ERIBULIN MESYLATE	MED	J9179
HARVONI	LEDIPASVIR-SOFOSBUVIR	PA	
HEMGENIX	ETRANACOGENE DEZAPARVOVEC-DRLB	MED	J1411
HEMLIBRA	EMICIZUMAB-KXWH	PA	
HEMOFIL M	ANTIHEMOPHILIC FACTOR (HUMAN)	PA	
HERCEPTIN	TRASTUZUMAB	MED	J9355

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
HERCEPTIN HYLECTA	TRASTUZUMAB & HYALURONIDASE-OYSK	MED	J9356
HERCESSI	TRASTUZUMAB-STRF	MED	Q5146
HERZUMA	TRASTUZUMAB-PKRB	MED	Q5113
HETLIOZ/ HETLIOZ LQ	TASIMELTEON	PA	
HIZENTRA	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS	MED	J1559
HULIO	ADALIMUMAB-FKJP	CE, PA	
HUMALOG JUNIOR KWIKPEN (0.5 UNIT DIAL)	INSULIN LISPRO (HUMAN) SOLN	CE, PA	
HUMALOG MIX, HUMALOG MIX KWIKPEN	INSULIN LISPRO PROTAMINE & LISPRO	CE, PA	
HUMALOG TEMPO	INSULIN LISPRO SOLN PEN-INJ W/TRANSMITTER PORT	CE, PA	
HUMALOG, HUMALOG KWIKPEN (1 UNIT DIAL)	INSULIN LISPRO (HUMAN) SOLN	CE, PA	
HUMATE-P	ANTIHEMOPHILIC FACTOR/VWF (HUMAN)	PA	
HUMATROPE	SOMATROPIN	CE, PA	
HUMIRA	ADALIMUMAB	PA	
HUMULIN N, HUMULIN N KWIKPEN	INSULIN NPH (HUMAN) (ISOPHANE)	PA	
HUMULIN R	INSULIN REGULAR (HUMAN) 100 UNIT/ML	PA	
HYALGAN	SODIUM HYALURONATE	MED	J7321
HYCAMTIN	TOPOTECAN	PA	
HYMOVIS	HYALURONAN	MED	J7322
HYQVIA	IMMUNE GLOBULIN-HYALURONIDASE	MED	J1575
HYRIMOZ	ADALIMUMAB-ADAZ SOLN	CE, PA	
IBRANCE	PALBOCICLIB	PA	
ICLUSIG	PONATINIB	PA	
IDACIO	ADALIMUMAB-AACF	CE, PA	
IDELVION	COAGULATION FACTOR IX (RECOMB) (RIX-FP)	PA	
IDHIFA	ENASIDENIB	PA	
ILARIS	CANAKINUMAB	MED	J0638
ILUMYA	TILDRAKIZUMAB	MED	J3245
IMBRUVICA	IBRUTINIB	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
IMDELLTRA	TARLATAMAB-DLLE	MED	J9026
IMFINZI	DURVALUMAB	MED	J9173
IMJUDO	TREMELIMUMAB	MED	J9347
IMKELDI	IMATINIB MESYLATE ORAL SOLN	CE, PA	
IMULDOSA IV	USTEKINUMAB-SRLF	MED	J3590; C9399
INFLECTRA	INFLIXIMAB-DYYB	MED	Q5103
INFLIXIMAB (UNBRANDED)	INFLIXIMAB	MED	J1745
INFUGEM	GEMCITABINE	MED	J9198
INGREZZA	VALBENAZINE	PA	
INJECTAFER	FERRIC CARBOXYMALTOSE	MED	J1439
INLYTA	AXITINIB	PA	
INPEFA	SOTAGLIFLOZIN	CE, PA	
INQOVI	DECITABINE-CEDAZURIDINE	PA	
INREBIC	FEDRATINIB	PA	
INSULIN ASPART PROTAMINE/ INSULIN ASPART, INSULIN ASPART PROTAMINE/ INSULIN ASPART FLEXPEN	INSULIN ASPART PROTAMINE/ INSULIN ASPART	CE, PA	
INSULIN ASPART, INSULIN ASPART FLEXPEN, INSULIN ASPART PENFILL	INSULIN ASPART	CE, PA	
INSULIN GLARGINE, INSULIN GLARGINE SOLOSTAR	INSULIN GLARGINE	CE, PA	
INSULIN LISPRO JUNIOR KWIKPEN (0.5 UNIT DIAL)	INSULIN LISPRO	CE, PA	
INSULIN LISPRO PROTAMINE/INSULIN LISPRO KWIKPEN	INSULIN LISPRO PROTAMINE/INSULIN LISPRO	CE, PA	
INSULIN LISPRO, INSULIN LISPRO KWIKPEN (1 UNIT DIAL)	INSULIN LISPRO	CE, PA	
INVOKAMET/ INVOKAMET XR	CANAGLIFLOZIN – METFORMIN	CE, PA	
INVOKANA	CANAGLIFLOZIN	CE, PA	
IQIRVO	ELAFIBRANOR	CE, PA	
IRESSA	GEFITINIB	PA	
ISTODAX	ROMIDEPSIN	MED	J9319
ISTURISA	OSILODROSTAT PHOSPHATE	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
ITOVEBI	INAVOLISIB	CE, PA	
IV IMMUNE GLOBULIN	INTRAVENOUS IMMUNE GLOBULIN	MED	J1599; J1566
IVABRADINE	IVABRADINE	PA	
IWILFIN	EFLORNITHINE HCL TAB	CE, PA	
IXEMPRA	IXABEPILONE	MED	J9207
IXINITY	COAGULATION FACTOR IX (RECOMBINANT)	PA	
IZERVAY	AVACINCAPTAD PEGOL	MED	J2782
JAKAFI	RUXOLITINIB	PA	
JAVYGTOR	SAPROPTERIN	PA	
JAYPIRCA	PIRTOBRUTINIB	CE, PA	
JELMYTO	MITOMYCIN	MED	J9281
JEMPERLI	DOSTARLIMAB-GXLY	MED	J9272
JENTADUETO	LINAGLIPTIN-METFORMIN	CE, PA	
JENTADUETO XR	LINAGLIPTIN-METFORMIN	CE, PA	
JEVTANA	CABAZITAXEL	MED	J9043
JIVI	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII PEG-AUCL)	PA	
JUBBONTI	DENOSUMAB-BBDZ	MED	Q5136
JUXTAPID	LOMITAPIDE	PA	
JYNARQUE	TOLVAPTAN	PA	
KADCYLA	ADO-TRASTUZUMAB EMTANSINE	MED	J9354
KALBITOR	ECALLANTIDE	MED	J1290
KALYDECO GRANULES 5.8 MG	IVACAFTOR	CE, PA	
KALYDECO PAK, TAB, GRANULES 13.4 mg	IVACAFTOR	PA	
KANJINTI	TRASTUZUMAB-ANNS	MED	Q5117
KANUMA	SEBELIPASE ALFA	MED	J2840
KAZANO	ALOGLIPTIN-METFORMIN HCL	CE, PA	
KEBILIDI	ELADOCAGENE EXUPARVOVEC-TNEQ	MED	J3590; C9399
KERENDIA	FINERENONE	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
KESIMPTA	OFATUMUMAB	PA	
KEVZARA	SARILUMAB	PA	
KEYTRUDA	PEMBROLIZUMAB	MED	J9271
KHAPZORY	LEVOLEUCOVORIN SODIUM	MED	J0642
KIMMTRAK	TEBENTAFUSP-TEBN	MED	J9274
KINERET	ANAKINRA	PA	
KISQALI	RIBOCICLIB	PA	
KISQALI/FEMARA DOSE PAK	RIBOCICLIB/LETROZOLE	PA	
KISUNLA	DONANEMAB-AZBT	MED	J0175
KOATE	ANTIHEMOPHILIC FACTOR (HUMAN)	PA	
KOATE-DVI	ANTIHEMOPHILIC FACTOR (HUMAN)	PA	
KOGENATE FS	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII)	PA	
KOMBIGLYZE XR	SAXAGLIPTIN-METFORMIN HCL	CE, PA	
KORLYM	MIFEPRISTONE (HYPERGLYCEMIA)	PA	
KOSELUGO	SELUMETINIB	PA	
KOVALTRY	ANTIHEMOPHILIC FACTOR RECOMB (RAHF-PFM)	PA	
KRAZATI	ADAGRASIB	PA	
KRYSTEXXA	PEGLOTICASE	MED	J2507
KUVAN	SAPROPTERIN	PA, CE (Brand only)	
KYMRIAH	TISAGENLECLEUCEL	MED	Q2042
KYPROLIS	CARFILZOMIB	MED	J9047
LAMZEDE	VELMANASE ALFA-TYCV	MED	J0217
LANTIDRA	DONISLECEL-JUJN	MED	J3590; C9399
LANTUS, LANTUS SOLOSTAR	INSULIN GLARGINE	CE, PA	
LAPATINIB DITOSYLATE	LAPATINIB DITOSYLATE	PA	
LAZCLUZE	LAZERTINIB MESYLATE	CE, PA	
LEDIPASVIR/SOFOSBUVIR	LEDIPASVIR-SOFOSBUVIR	PA	
LEMTRADA	ALEMTUZUMAB	MED	J0202

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
LENMELDY	ATIDARSAGENE AUTOTEMCEL	MED	J3590; C9399
LENVIMA	LENVATINIB MESYLATE	PA	
LEQEMBI	LECANEMAB	MED	J0174
LEQVIO	INCLISIRAN SODIUM	MED	J1306
LETAIRIS	AMBRISENTAN	PA	
L-GLUTAMINE	GLUTAMINE (SICKLE CELL) POWD PACK	PA	
LIBTAYO	CEMPIIMAB-RWLC	MED	J9119
LIQREV	SILDENAFIL CITRATE ORAL SUSP	CE, PA	
LIRAGLUTIDE	LIRAGLUTIDE SOLN PEN-INJECTOR	CE, PA	
LIVDELZI	SELADELPAR LYSINE	CE, PA	
LONSURF	TRIFLURIDINE-TIPIRACIL	PA	
LOQTORZI	TORIPALIMAB-TPZI	MED	J3263
LORBRENA	LORLATINIB	PA	
LUCENTIS	RANIBIZUMAB	MED	J2778
LUMAKRAS	SOTORASIB	PA	
LUMIZYME	ALGLUCOSIDASE ALFA	MED	J0221
LUMOXITI	MOXETUMOMAB PASUDOTOX-TDFK	MED	J9313
LUMRYZ	SODIUM OXYBATEFOR ORAL ER SUSP	CE, PA	
LUNSUMIO	MOSUNETUZUMAB-AXGB	MED	J9350
LUPKYNIS	VOCLOSPORIN	PA	
LUTATHERA	LUTETIUM LU 177	MED	A9513
LUXTURNA	VORETIGENE	MED	J3398
LYFGENIA	LOVOTIBEGLOGENE AUTOTEMCEL	MED	J3394
LYMPHIR	DENILEUKIN DIFTITOX-CXDL	MED	J9999; C9399
LYNPARZA	OLAPARIB	PA	
LYSODREN	MITOTANE	PA	
LYTGOBI	FUTIBATINIB	PA	
LYUMJEV TEMPO PEN	INSULIN LISPRO-AABC SOLN PEN-INJ W/TRANSMIT PORT	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
LYUMJEV, LYUMJEV KWIKPEN	INSULIN LISPRO	CE, PA	
LYVISPAH GRANULES PACKET	BACLOFEN GRANULES PACKET	CE, PA	
MACI	AUTOLOGOUS CULTURED CHONDROCYTE ON COLLAGEN MEMBRANE SHEET	MED ND	J7330
MARGENZA	MARGETUXIMAB-CMKB	MED	J9353
MATULANE	PROCARBAZINE	PA	
MAVENCLAD	CLADRIBINE	PA	
MAVYRET	GLECAPREVIR-PIBRENTASVIR	PA	
MAYZENT	SIPONIMOD	PA	
MEKINIST	TRAMETINIB	PA	
MEKTOVI	BINIMETINIB	PA	
MEPSEVII	VESTRONIDASE ALFA	MED	J3397
MIFEPREX	MIFEPRISTONE	CE, PA	
MIGRANAL	DIHYDROERGOTAMINE MESYLATE NASAL SPRAY	CE, PA	
MONJUVI	TAFASITAMAB - CXIX	MED	J9349
MONOFERRIC	FERRIC DERISOMALTOSE	MED	J1437
MONOVISC	HYALURON	MED	J7327
MOUNJARO	TIRZEPATIDE	PA	
MOZOBIL	PLERIXAFOR	MED	J2562
MULPLETA	LUSUTROMBOPG	PA	
MVASI	BEVACIZUMAB-AWWB	MED	Q5107
MYALEPT	METRELEPTIN	PA	
MYFEMBREE	RELUGOLIX-ESTRADIOL-NORETHINDRONE ACETATE	PA	
NAGLAZYME	GALSULFASE	MED	J1458
NERLYNX	NERATINIB	PA	
NESINA	ALOGLIPTIN BENZOATE	CE, PA	
NEXAVAR	SORAFENIB	PA	
NEXLETOL	BEMPEDOIC ACID	PA	
NEXLIZET	BEMPEDOIC ACID	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
NEXVIAZYME	AVALGLUCOSIDASE ALFA	MED	J0219
NGENLA	SOMATROGON-GHLA SOLUTION PEN-INJECTOR	CE, PA	
NIKTIMVO	AXATILIMAB-CSFR	MED	J3590; C9399
NINLARO	IXAZOMIB	PA	
NORDITROPIN	SOMATROPIN	PA	
NORTHERA	DROXIDOPA	CE, PA	
NOVOEIGHT	ANTIHEMOPHILIC FACT RCMB (BD TRUNC-RFVIII)	PA	
NOVOSEVEN RT	COAGULATION FACTOR VIIA (RECOMB)	PA	
NOXAFIL packet, suspension	POSACONAZOLE packet, suspension	PA	
NOXAFIL tab	POSACONAZOLE tab	PA, CE (Brand only)	
NPLATE	ROMIPLOSTIM	MED	J2802
NUBEQA	DAROLUTAMIDE	PA	
NUCALA autoinjector or prefilled syringe (Self-Administered)	MEPOLIZUMAB	PA	
NUCALA vial (Healthcare Administered)	MEPOLIZUMAB	MED	J2182
NURTEC	RIMEGEPANT SULFATE	PA	
NUTROPIN/NUTROPIN AQ	SOMATROPIN	CE, PA	
NUWIQ	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,SIM)	PA	
NYVEPRIA	PEGFILGRASTIM-APGF	MED	Q5122
OALIVA	OBETICHOLIC ACID	PA	
OCREVUS	OCRELIZUMAB	MED	J2350
OCREVUS ZUNOVO	OCRELIZUMAB;HYALURONIDASE-OCSQ	MED	J3590; C9399
OCTAGAM	IMMUNE GLOBULIN (HUMAN) IV	MED	J1568
ODACTRA	DUST MITE MIXED EXTRACT	PA	
ODOMZO	SONIDEGIB	PA	
OFEV	NINTEDANIB	PA	
OGIVRI	TRASTUZUMAB-DKST	MED	Q5114
OGSIVEO	NIROGACESTAT HYDROBROMIDE	CE, PA	
OJEMDA	TOVORAFENIB	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
OJJAARA	MOMELOTINIB DIHYDROCHLORIDE	CE, PA	
OLUMIANT	BARICITINIB	PA	
OMISIRGE	OMIDUBICEL-ONLV	MED	J3590; C9399
OMNIPOD 5 G6	INSULIN INFUSION DISPOSABLE PUMP	MED+	N/A
OMNIPOD CLASSIC	INSULIN INFUSION DISPOSABLE PUMP	MED+	N/A
OMNIPOD DASH	INSULIN INFUSION DISPOSABLE PUMP	MED+	N/A
OMNITROPE	SOMATROPIN	PA	
OMVOH auto-injector (Self-Administered)	MIRIKIZUMAB-MRKZ	CE, PA	
OMVOH IV vial (Healthcare Administered)	MIRIKIZUMAB-MRKZ	MED	J2267
ONCASPAR	PEGASPARGASE	MED	J9266
ONGLYZA	SAXAGLIPTIN HCL	CE, PA	
ONIVYDE	IRINOTECAN LIPOSOMAL	MED	J9205
ONPATTRO	PATISIRAN	MED	J0222
ONTRUZANT	TRASTUZUMAB-DTTB	MED	Q5112
ONUREG	AZACITIDINE TAB	PA	
OPDIVO	NIVOLUMAB	MED	J9299
OPDIVO QVANTIG	NIVOLUMAB AND HYALURONIDASE-NVHY	MED	J9999; C9399
OPDUALAG	NIVOLUMAB-RELATLIMAB-RMBW	MED	J9298
OPSUMIT	MACITENTAN	PA	
OPSYNVI	MACITENTAN-TADALAFIL	CE, PA	
OPUVIZ	AFLIBERCEPT-YSZY	MED	J3590; C9399
ORALAIR	MIXED GRASS POLLENS ALLERGEN EXTRACT	CE, PA	
ORENCIA IV vial (Healthcare Administered)	ABATACEPT	MED	J0129
ORENCIA prefilled syringe or auto-injector (Self-Administered)	ABATACEPT	PA	
ORENITRAM	TREPROSTINIL	PA	
ORGOVYX	ELEXACAF-TEZACAF-IVACATOR	PA	
ORIAHNN	RELUGOLIX	PA	
ORLISSA	ELAGOLIX	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
ORKAMBI	LUMACAFTOR-IVACAFTOR	PA	
ORLADEYO	BEROTRALSTAT	CE, PA	
ORSERDU	ELACESTRANT HYDROCHLORIDE	CE, PA	
ORTHOVISC	HYALURONAN	MED	J7324
OSENI	ALOGLIPTIN-PIOGLITAZONE	CE, PA	
OTEZLA	APREMILAST	PA	
OTULFI IV	USTEKINUMAB-AAUZ	MED	J3590; C9399
OXBRYTA	VOXELOTOR	PA	
OXERVATE	CENEGERMIN-BKBJ	PA	
OXLUMO	LUMASIRAN	MED	J0224
OZEMPIC	SEMAGLUTIDE	PA	
OZOBAX	BACLOFEN	CE, PA	
PACLITAXEL ALBUMIN-BOUND	PACLITAXEL ALBUMIN-BOUND	MED	J9264
PADCEV	ENFORTUMAB VEDOTIN-EJFV	MED	J9177
PALYNZIQ	PEGVALIASE-PQPZ	PA	
PANCREAZE	PANCRELIPASE (LIP-PROT-AMYL)	CE, PA	
PANZYGA	IMMUNE GLOBULIN (HUMAN)-IFAS IV	MED	J1576
PAVBLU	AFLIBERCEPT-AYYH	MED	J3590; C9399
PEMAZYRE	PEMIGATINIB	PA	
PEMFEXY	PEMETREXED	MED	J9304
PEMRYDI RTU	PEMETREXED	MED	J9324
PERJETA	PERTUZUMAB	MED	J9306
PERTZYE	PANCRELIPASE (LIP-PROT-AMYL)	CE, PA	
PHESGO	PERTUZUMAB – TRASTUZUMAB – HYALURONIDASE – ZZXF	MED	J9316
PIASKY	CROVALIMAB-AKKZ	MED	J1307
PIQRAY	ALPELISIB	PA	
PIRFENIDONE	PIRFENIDONE	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
PLEGRIDY	PEGINTERFERON BETA-1A	PA	
PLUVICTO	LUTETIUM LU 177	MED	A9607
POLIVY	POLATUZUMAB	MED	J9309
POMALYST	POMALIDOMIDE	PA	
POMBILITI	CIPAGLUCOSIDASE ALFA-ATGA	MED	J1203
PONVORY	PONESIMOD	CE, PA	
POSFREA	PALONOSETRON	MED	J2468
POTELIGEO	MOGAMULIZUMAB	MED	J9204
PRALUENT	ALIROCUMAB	CE, PA	
PRIVIGEN	IMMUNE GLOBULIN (HUMAN) IV	MED	J1459
PROCYSBI	CYSTEAMINE BITARTRATE	CE, PA	
PROFILNINE	FACTOR IX COMPLEX	PA	
PROLIA	DENOSUMAB	MED	J0897
PROMACTA	ELTROMBOPAG	PA	
PROVENGE	SIPULEUCEL-T	MED	Q2043
PYZCHIVA IV	USTEKINUMAB-TTWE	MED	Q9997
PYRUKYND	MITAPIVAT	PA	
QALSODY	TOFERSEN	MED	J1304
QINLOCK	RIPRETINIB	PA	
QTERN	DAPAGLIFLOZIN – SAXAGLIPTIN	CE, PA	
QTERN	DAPAGLIFLOZIN – SAXAGLIPTIN	CE, PA	
QULIPTA	ATOGEPAANT	PA	
QUTENZA	CAPSAICIN PATCH	MED	J7336
RADICAVA	EDARAVONE	MED	J1301
RADICAVA ORS	EDARAVONE	PA	
RAGWITEK	SHORT RAGWEED POLLEN ALLERGEN EXTRACT	PA	
REBIF	INTERFERON β -1a	PA	
REBINYN	COAGULATION FACTOR IX RECOMB GLYCOPEGYLATED	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
REBLOZYL	LUSPATERCEPT-AAMT	MED	J0896
RECOMBINATE	ANTIHEMOPHILIC FACTOR RECOMB (RFVIII)	PA	
RECORLEV	LEVOKETOCONAZOLE	CE, PA	
RELYVRIO	SODIUM PHENYL BUTYRATE-TAURURSODIOL	PA	
REMICADE	INFLIXIMAB	MED	J1745
RENFLEXIS	INFLIXIMAB-ABDA	MED	Q5104
REPATHA	EVOLOCUMAB	PA	
RETEVMO	SELPERCATINIB	PA	
RETHYMIC	ALLOGENEIC PROCESSED THYMUS TISSUE-AGDC	MED	J3590; C9399
RETIN-A, RETIN-A MICRO	TRETINOIN	PA, CE (Brand only)	
REVATIO	SILDENAFIL	PA, CE (Brand only)	
REVCOVI	ELAPEADEMASE-LVLR	MED	J3590; C9399
REVLIMID	LENALIDOMIDE	PA	
REVUFORJ	REVUMENIB CITRATE	CE, PA	
REYVOW	LASMIDITAN SUCCINATE	PA	
REZLIDHIA	OLUTASIDENIB	PA	
REZUROCK	BELUMOSUDIL MESYLATE	PA	
REZVOGLAR KWIKPEN	INSULIN GLARGINE-AGLR SOLN PEN-INJECTOR	CE, PA	
RIABNI	RITUXIMAB-ARRX	MED	Q5123
RIASTAP	FIBRINOGEN CONC (HUMAN)	PA	
RINVOQ	UPADACITINIB	PA	
RINVOQ LQ	UPADACITINIB	CE, PA	
RITUXAN	RITUXIMAB	MED	J9312
RITUXAN HYCELA	RITUXIMAB-HYALURONIDASE	MED	J9311
RIXUBIS	COAGULATION FACTOR IX (RECOMBINANT)	PA	
ROCTAVIAN	VALOCTOCOGENE ROXAPARVOVEC-RVOX	MED	J1412
ROLVEDON	EFLAPEGRASTIM-XNST	MED	J1449

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
ROMIDEPSIN	ROMIDEPSIN	MED	J9318
ROZLYTREK	ENTRECTINIB	PA	
RUBRACA	RUCAPARIB	CE, PA	
RUCONEST	C1 ESTERASE INHIBITOR (RECOMBINANT)	MED	J0596
RUXIENCE	RITUXIMAB-PVVR	MED	Q5119
RUZURGI	AMIFAMPRIDINE	PA	
RYBELSUS	SEMAGLUTIDE	PA	
RYBREVANT	AMIVANTAMAB-VMJW	MED	J9061
RYDAPT	MIDOSTAURIN	PA	
RYLAZE	ASPARAGINASE ERWINIA CHRYS	MED	J9021
RYONCIL	REMESTEMCEL-L-RKND	MED	J3590; C9399
RYPLAZIM	PLASMINOGEN, HUMAN-TVMH	MED	J2998
RYSTIGGO	ROZANOLIXIZUMAB-NOLI	MED	J9333
RYTELO	IMETELSTAT	MED	J0870
RYZNEUTA	EFBEMALENOGRASTIM ALFA-VUXW	MED	J9361
SAIZEN	SOMATROPIN	CE, PA	
SAIZENPREP RECONSTITUTIONKIT	SOMATROPIN	CE, PA	
SAJAZIR	ICATIBANT ACETATE	PA	
SAMSCA	TOLVAPTAN	PA	
SAPHNELO	ANIFROLUMAB-FNIA	MED	J0491
SAPROPTERIN DIHYDROCHLORIDE	SAPROPTERIN DIHYDROCHLORIDE	PA	
SARCLISA	ISATUXIMAB-IRFC	MED	J9227
SCEMBLIX	ASCIMINIB HCL	PA	
SEGLUROMET	ERTUGLIFLOZIN – METFORMIN	CE, PA	
SELARSDI IV	USTEKINUMAB-AEKN	MED	Q9998
SEMGLEE (ONLY NDCs 49502-0196-71, 49502-0196-75, 49502-0195-80)	INSULIN GLARGINE	CE, PA	
SENSIPAR	CINACALCET	PA, CE (Brand only)	
SEROSTIM	SOMATROPIN	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
SEVENFACT	COAGULATION FACTOR VIIA (RECOM)-JNCW	PA	
SILIQ	BRODALUMAB	CE, PA	
SIMLANDI	ADALIMUMAB-RYVK	CE, PA	
SIMPONI (Self-Administered)	GOLIMUMAB	PA	
SIMPONI ARIA (Healthcare Administered)	GOLIMUMAB	MED	J1602
SITAGLIPTIN/METFORMIN HYDROCHLORIDE	SITAGLIPTIN FREE BASE-METFORMIN HCL	CE, PA	
SKYRIZI IV vial (Healthcare Administered)	RISANKIZUMAB-RZAA	MED	J2327
SKYRIZI prefilled syringe or cartridge (Self-Administered)	RISANKIZUMAB-RZAA	PA	
SKYSONA	ELIVALDOGENE AUTOTEMCEL	MED	J3590; C9399
SKYTROFA	LONAPEGSOMATROPIN-TCGD	PA	
SOFOSBUVIR/VELPATASVIR	SOFOSBUVIR-VELPATASVIR	PA	
SOGROYA	SOMAPACITAN-BECO SOLUTION PEN-INJECTOR	CE, PA	
SOLIRIS	ECULIZUMAB	MED	J1300
SOTYKTU	DEUCRAVACITINIB	CE, PA	
SOVALDI	SOFOSBUVIR	PA	
SPEVIGO	SPESOLIMAB-SBZO SUBCUTANEOUS SOLN PREF SYR	PA	
SPEVIGO IV	SPESOLIMAB	MED	J1747
SPINRAZA	NUSINERSEN	MED	J2326
SPRYCEL	DASATINIB	PA	
STEGLATRO	ERTUGLIFLOZIN L-PYROGLUTAMIC ACID	CE, PA	
STEGLUJAN	ERTUGLIFLOZIN – SITAGLIPTIN	CE, PA	
STELARA IV vial (Healthcare Administered)	USTEKINUMAB	MED	J3358
STELARA prefilled syringe (Self-Administered)	USTEKINUMAB	PA	
STEQEYMA IV vial (Healthcare Administered)	USTEKINUMAB-STBA	MED	J3590; C9399
STIMUFEND	PEGFILGRASTIM-FPGK	MED	Q5127
STIVARGA	REGORAFENIB	PA	
STRENSIQ	ASFOTASE ALFA	PA	
SUNOSI	SOLRIAMFETOL HCL	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
SUPARTZ FX	SODIUM HYALURONATE	MED	J7321
SUSTOL	GRANISETRON EXTENDED RELEASE	MED	J1627
SUSVIMO	RANIBIZUMAB	MED	J2779
SUTENT	SUNITINIB	PA	
SYFOVRE	PEGCETACOPLAN	MED	J2781
SYLATRON	PEGINTERFERON ALFA-2B	PA	
SYLVANT	SILTUXIMAB	MED	J2860
SYMDEKO	TEZACAFTOR-IVACAFTOR	CE, PA	
SYNAGIS	PALIVIZUMAB IM SOLUTION	MED	90378
SYNOJOYNT	SODIUM HYALURONATE	MED	J7331
SYNRIBO	OMACETAXINE MEPESUCCINATE	MED	J9262
SYNVISC	HYLAN INTRA-ARTICULAR	MED	J7325
SYNVISC-ONE	HYLAN INTRA-ARTICULAR	MED	J7325
TABRECTA	CAPMATINIB	PA	
TADLIQ	TADALAFIL	CE, PA	
TAFINLAR	DABRAFENIB	PA	
TAGRISSO	OSIMERTINIB	PA	
TAKHZYRO	LANADELUMAB	PA	
TALTZ	IXEKIZUMAB	CE, PA	
TALVEY	TALQUETAMAB-TGVS	MED	J3055
TALZENNA	TALAZOPARIB	PA	
TARCEVA	ERLOTINIB	PA	
TARGRETIN	BEXAROTENE	PA, CE (Brand only)	
TARPEYO	BUDESONIDE DR	CE, PA	
TASCENSO ODT	FINGOLIMOD LAURYL	CE, PA	
TASIGNA	NILOTINIB	PA	
TASIMELTEON	TASIMELTEON	PA	
TAVALISSE	FOSTAMATINIB	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
TAZORAC	TAZAROTENE	PA, CE (Brand only)	
TAZVERIK	TAZEMETOSTAT	PA	
TECARTUS	BREXUCABTAGENE AUTOLEUCEL	MED	Q2053
TECELRA	AFAMITRESGENE AUTOLEUCEL	MED	J9999; C9399
TECENTRIQ	ATEZOLIZUMAB	MED	J9022
TECENTRIQ HYBREZA	ATEZOLIZUMAB and HYALURONIDASE-TQJS	MED	J9999; C9399
TECFIDERA	DIMETHYL FUMARATE	PA, CE (Brand only)	
TECVAYLI	TECLISTAMAB-CQYV	MED	J9380
TEGSEDI	INOTERSEN	PA	
TEMODAR	TEMOZOLOMIDE	PA, CE (Brand only)	
TEPEZZA	TEPROTUMUMAB-TRBW	MED	J3241
TEPMETKO	TEPOTINIB	PA	
TERIPARATIDE	TERIPARATIDE (RECOMBINANT)	PA	
TEVIMBRA	TISLELIZUMAB-JSGR	MED	J9329
TEZSPIRE (Healthcare Administered)	TEZEPELUMAB-EKKO	MED	J2356
TEZSPIRE (Self-Administered)	TEZEPELUMAB-EKKO	PA	
THALOMID	THALIDOMIDE	PA	
TIBSOVO	IVOSIDENIB	PA	
TIVDAK	TISOTUMAB VEDOTIN TFTV	MED	J9273
TOFIDENCE	TOCILIZUMAB-BAVI	MED	Q5133
TOLVAPTAN	TOLVAPTAN	PA	
TRACLEER	BOSENTAN	PA	
TRADJENTA	LINAGLIPTIN	CE, PA	
TRAZIMERA	TRASTUZUMAB-QYYP	MED	Q5116
TREANDA	BENDAMUSTINE	MED	J9033
TREMFYA	GUSELKUMAB	PA	
TREMFYA IV	GUSELKUMAB	MED	J1628
TRETINOIN MICROSPHERE	TRETINOIN MICROSPHERE GEL	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
TRIKAFTA	ELEXACAFTOR/ TEZECAFTOR/ IVACAFTOR AND IVACAFTOR	PA	
TRILURON	SODIUM HYALURONATE	MED	J7332
TRIVISC	SODIUM HYALURONATE	MED	J7329
TRODELVY	SACITUZUMAB	MED	J9317
TRUDHESA	DIHYDROERGOTAMINE MESYLATE	CE, PA	
TRULICITY	DULAGLUTIDE	PA	
TRUQAP	CAPIVASERTIB	CE, PA	
TRUSELTIQ	INFIGRATINIB	PA	
TRUXIMA	RITUXUMAB-ABBS	MED	Q5115
TUKYSA	TUCATINIB	PA	
TURALIO	PXIDARTINIB	PA	
TWYNEO	TRETINOIN-BENZOYL PEROXIDE	CE, PA	
TYENNE	TOCILIZUMAB-AAZG	CE, PA	
TYENNE IV	TOCILIZUMAB-AAZG	MED	Q5135
TYKERB	LAPATINIB	PA	
TYMLOS	ABALOPARATIDE	PA	
TYRUKO	NATALIZUMAB-SZTN	MED	Q5134
TYSABRI	NATALIZUMAB	MED	J2323
TYVASO	TREPROSTINOL	PA	
TZIELD	TEPLIZUMAB-MZWV	MED	J9381
UBRELVY	UBROGEPANT	PA	
UDENYCA/UDENYCA ONBODY	PEGFILGRASTIM-CBQV	MED	Q5111
ULTOMIRIS	RAVUILIZUMAB	MED	J1303
UNLOXCYT	COSIBELIMAB-IPDL	MED	J9999; C9399
UPLIZNA	INEBILIZUMAB	MED	J1823
UPTRAVI	SELEXIPAG	PA	
VABYSMO	FARICIMAB-SVOA	MED	J2777
VANFLYTA	QUIZARTINIB DIHYDROCHLORIDE TAB	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
VASCEPA	ICOSAPENT ETHYL	PA	
VECTIBIX	PANITUMUMAB	MED	J9303
VEGZELMA	BEVACIZUMAB-ADCD	MED	Q5129
VELSIPITY	ETRASIMOD ARGININE TAB	CE, PA	
VENCLEXTA	VENETOCLAX	PA	
VENTAVIS	ILOPROST	PA	
VEOPOZ	POZELIMAB-BBFG	MED	J9376
VERZENIO	ABEMACICLIB	PA	
VFEND	VORICONAZOLE	PA, CE (Brand only)	
VICTOZA	LIRAGLUTIDE	CE, PA	
VILTEPSO	VILTOLARSEN	MED	J1427
VIMIZIM	ELOSULFASE ALFA	MED	J1322
VIOKACE	PANCRELIPASE (LIP-PROT-AMYL)	CE, PA	
VISCO-3	SODIUM HYALURONATE	MED	J7321
VITRAKVI	LAROTRECTINIB	PA	
VIVIMUSTA	BENDAMUSTINE	MED	J9056
VIVJOA	OTESECONAZOLE	CE, PA	
VIZIMPRO	DACOITINIB	PA	
VONJO	PACRITINIB	PA	
VONVENDI	VON WILLEBRAND FACTOR (RECOMBINANT)	PA	
VORANIGO	VORASIDENIB	CE, PA	
VOSEVI	SOFOBUVIR-VELPATASVIR-VOXILAPREVIR	PA	
VOTRIENT	PAZOPANIB	PA	
VPRIV	VELAGLUCERASE ALFA	MED	J3385
VUMERITY	DIROXIMEL FUMARATE	PA	
VYEPTI	EPTINEZUMAB-JJMR	MED	J3032
VYJUVEK	BEREMAGENE GEPERPAVEC-SVDT	MED	J3401
VYLOY	ZOLBETUXIMAB-CLZB	MED	J9999; C9399

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
VYNDAMAX	TAFAMIDIS	PA	
VYNDAQEL	TAFAMIDIS	PA	
VYONDYS-53	GOLODIRSEN	MED	J1429
VYVGART	EFGARTIGIMOD ALFA-FCAB	MED	J9332
VYVGART HYTRULO	EFGARTIGIMOD ALFA-HYALURONIDASE-QVFC	MED	J9334
WAINUA	EPLONTERSEN SODIUM SUBCUTANEOUS SOLN AUTO-INJ	CE, PA	
WAKIX	PITOLISANT	CE, PA	
WELIREG	BELZUTIFAN	PA	
WEZLANA	USTEKINUMAB-AUUB SOLN PREFILLED SYRINGE	CE, PA	
WEZLANA IV	USTEKINUMAB-AUUB	MED	Q5138
WILATE	ANTIHEMOPHILIC FACTOR/VWF (HUMAN)	PA	
WINREVAIR	SOTATERCEPT-CSRK FOR SUBCUTANEOUS SOLN KIT	CE, PA	
WYOST	DENOSUMAB-BBDZ	MED	Q5136
XALKORI	CRIZOTINIB	PA, CE	
XELJANZ, XELJANZ XR	TOFACITINIB	PA	
XELODA	CAPECITABINE	PA, CE (Brand only)	
XEMBIFY	IMMUNE GLOBULIN (HUMAN) SUBCUTANEOUS	MED	J1558
XENAZINE	TETRABENAZINE	PA, CE (Brand only)	
XENPOZYME	OLIPUDASE ALFA-RPCP	MED	J0218
XERMELO	TELOTRISTAT	PA	
XGEVA	DENOSUMAB	MED	J0897
XOLAIR prefilled syringe, auto-injector (Self-Administered)	OMALIZUMAB	PA	
XOLAIR vial (Healthcare Administered)	OMALIZUMAB	MED	J2357
XOLREMDI	MAVORIXAFOR	PA	
XOSPATA	GILTERITINIB	PA	
XPOVIO	SELINEXOR	PA	
XTANDI	ENZALUTAMIDE	PA	
XYNTHA	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,MOR)	PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
XYNTHA SOLOFUSE	ANTIHEMOPHIL FACT RCMB (BDD-RFVIII,MOR)	PA	
XYREM	SODIUM OXYBATE	CE, PA	
XYWAV	CALCIUM, MAG, POTASSIUM, & SOD OXYBATES	PA	
YARGESA	MIGLUSTAT	CE, PA	
YERVOY	IPILIMUMAB	MED	J9228
YESAFILI	AFLIBERCEPT-JBVF	MED	J3590; C9399
YESCARTA	AXICABTAGENE CILOLEUCEL	MED	Q2041
YESINTEK IV vial (Healthcare Administered)	USTEKINUMAB-KFCE	MED	J3590; C9399
YIMMUGO	IMMUNE GLOBULIN	MED	J1599
YONDELIS	TRABECTEDIN	MED	J9352
YONSA	ABIRATERONE	PA	
YUFLYMA	ADALIMUMAB-AATY	CE, PA	
YUSIMRY	ADALIMUMAB-AQVH	CE, PA	
ZALTRAP	ZIV-AFLIBERCEPT	MED	J9400
ZAVESCA	MIGLUSTAT	PA, CE (Brand only)	
ZAVZPRET	ZAVEGEPANT	CE, PA	
ZEJULA	NIRAPARIB	PA	
ZELBORAF	VEMURAFENIB	PA	
ZEPATIER	ELBASVIR-GRAZOPREVIR	CE, PA	
ZEPOSIA	OZANIMOD	PA	
ZEPOSIA	OZANIMOD	PA	
ZEPZELCA	LURBINECTEDIN	MED	J9223
ZIEXTENZO	PEGFILGRASTIM-BMEZ	MED	Q5120
ZIIHERA	ZANIDATAMAB-HRII	MED	J9999; C9399
ZILRETTA	TRIAMCINOLONE ACETONIDE	MED	J3304
ZIRABEV	BEVACIZUMAB-BVZR	MED	Q5118
ZITUVIO	SITAGLIPTIN TAB	CE, PA	
ZITUVIMET XR	SITAGLIPTIN FREE BASE-METFORMIN HCL	CE, PA	

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024 AND 2025	PROCEDURE CODE (MED ONLY)
ZOKINVY	LONAFARNIB	PA	
ZOLGENSMA	ONASEMNOGENE	MED	J3399
ZOLINZA	VORINOSTAT	PA	
ZOMACTON	SOMATROPIN	CE, PA	
ZORBTIVE	SOMATROPIN	CE, PA	
ZYDELIG	IDELALISIB	PA	
ZYKADIA	CERITINIB	PA	
ZYMFENTRA	INFLIXIMAB-DYYB	CE, PA	
ZYNLONTA	LONCASTUXIMA TESIRINE-LPYL	MED	J9359
ZYNTEGLO	BETIBEGLOGENE AUTOTEMCEL	MED	J3393
ZYNYZ	RETIFANLIMAB-DLWR IV	MED	J9345
ZYTIGA	ABIRATERONE	PA	

CATEGORY	BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024	QHP 2025
WEIGHT LOSS Not all benefit plans cover Weight Loss medications. Please contact a Member Services representative for specific coverage information.	ADIPEX-P	PHENTERMINE	BENEFIT EXCLUSION	CE, PA
	BENZPHETAMINE	BENZPHETAMINE	BENEFIT EXCLUSION	CE, PA
	CONTRAVE	NALTREXONE/BUPROPION	BENEFIT EXCLUSION	CE, PA
	DIETHYLPROPION	DIETHYLPROPION	BENEFIT EXCLUSION	CE, PA
	IMCIVREE	SETMELANOTIDE	BENEFIT EXCLUSION	PA
	LOMAIRA	PHENTERMINE	BENEFIT EXCLUSION	PA
	QSYMIA	PHENTERMINE/TOPIRAMATE	BENEFIT EXCLUSION	PA
	ORLISTAT	ORLISTAT	BENEFIT EXCLUSION	PA
	PHENDIMETRAZINE	PHENDIMETRAZINE	BENEFIT EXCLUSION	CE, PA
	XENICAL	ORLISTAT	BENEFIT EXCLUSION	PA
	PHENTERMINE	PHENTERMINE	BENEFIT EXCLUSION	CE, PA

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

CATEGORY	BRAND DRUG NAME	GENERIC DRUG NAME	QHP 2024	QHP 2025
WEIGHT MANAGEMENT Not all benefit plans cover Weight Management medications. Please contact a Member Services representative for specific coverage information.	SAXENDA	LIRAGLUTIDE	BENEFIT EXCLUSION	PA
	WEGOVY	SEMAGLUTIDE	BENEFIT EXCLUSION	PA
	ZEPBOUND	TIRZEPATIDE	BENEFIT EXCLUSION	PA

**Blue Cross Blue Shield of North Dakota
Restricted Use List – Prior Approval**

Drugs with Benefit Quantity Limits: The following list represents the drugs subject to a limited dispensing amount.				
SEXUAL DYSFUNCTION**, ORAL		Daily and as-needed use prescriptions are not allowed concomitantly		
BRAND NAME	GENERIC NAME	FORMULARY STATUS	Quantity Limit	
CIALIS 10 mg, 20 mg	TADALAFIL	NF	A Combined Total of 18 tablets per 90 Days	A member can receive up to a combined total of 18 tablets per 90 days. The claims system will not allow any quantity >18 in any 90-day claims period.
LEVITRA	VARDENAFIL	NF		
STAXYN	VARDENAFIL	NF		
STENDRA	AVANAFIL	NF		
VIAGRA	SILDENAFIL	NF		
CIALIS Once-Daily Use 2.5 mg, 5 mg**	TADALAFIL	NF	1 tab/day	
ADDYI	FLIBANSERIN	NF	1 tab/day	
VYLEESI (Injectable)	BREMELANOTID	NF	6 doses/30 days	

**Medications used to treat sexual dysfunction are a benefit exclusion under Qualified Health Plans. Cialis Once Daily 5mg may be eligible for a Coverage Exception under Qualified Health Plans to treat benign prostatic hypertrophy (BPH).